Current Status of Chemoprevention in Barrett ’s Esophagus

Candidates for chemoprevention in Barrett ’s esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin. Proton pump inhibitor therapy and aspirin are the most promising agents. Data suggest that aspir in and proton pump inhibitor therapy can decrease the risk of neoplastic progression in Barrett’s esophagus. Further, the combination of aspirin and proton pump inhibitor therapy decrease all-cause mortality by approximately 33%. Future guideline groups need to evaluate the evidence rigorously, bu t the combination of proton pump inhibitor therapy and aspirin is promising.

Source: Gastrointestinal Endoscopy Clinics of North America - October 26, 2020 Category: Gastroenterology Authors: Paul Moayyedi, Hashem B. El-Serag Source Type: research